Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-06-06 07:09:15 ET More on Novartis, Roche, etc. Novartis AG (NVS) Investor Event at ASCO Conference Call (Transcript) Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Roche Is Joining The Obesity Party But Questions Remain SA Asks: Which weight-lo...
2024-06-03 14:01:03 ET More on Gilead Sciences, Arcus Biosciences Gilead Sciences: Seriously Undervalued At Peak Pessimism Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO ...
2024-06-02 14:00:00 ET PD-1/PD-L1 inhibitors, some of the most commonly used cancer therapies, achieved $52B in spending worldwide in 2023, a number expected to reach $90B in 2028. Examples include Merck's ( NYSE: MRK ) Keytruda (pembrolizumab), Bristol Myers Squibb's ( NYSE: BM...
2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...
2024-05-30 16:10:00 ET Summary The global market for GLP-1 therapies now looks on pace to top $100 billion. GLP-1 pioneers such as Eli Lilly, Novo Nordisk, could be joined by new players Amgen, Altimmune, Pfizer, Viking, Roche, and privately held Boehringer Ingelheim that have GLP...
2024-05-29 10:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-29 10:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-29 09:25:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options – – Additional analyses of INAVO120 will be presented in an oral abstract session at the 2024 American Society of Clinical Onc...
Roche and Hitachi High-Tech extend their long-standing partnership TOKYO, May 28, 2024 - (JCN Newswire) - Hitachi High-Tech Corporation announced that Roche and Hitachi High-Tech have extended their partnership, committing to at least 10 years of additional collaboration. Bringing t...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...